C
Christopher D. Lao
Researcher at University of Michigan
Publications - 127
Citations - 24365
Christopher D. Lao is an academic researcher from University of Michigan. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 35, co-authored 100 publications receiving 17710 citations.
Papers
More filters
Efficacy and Safety in Key Patient Subgroups of Nivolumab (Nivo) Alone Or Combined with Ipilimumab (Ipi) Versus Ipi Alone in Treatment-Naive Patients with Advanced Melanoma
James Larkin,Chiarion-Sileni,Ricardo J. Gonzalez,J.-J. Grob,Charles Lance Cowey,Christopher D. Lao,John Wagstaff,David W. Hogg,A. Hill,Matteo S. Carlino,Pascal Wolter,C. Lebbé,Jacob Schachter,Luc Thomas,J Hassal,Paul Lorigan,Dana Walker,Joel Jiang,F.S. Hodi,Jedd D. Wolchok +19 more
Journal ArticleDOI
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Vincent T. Ma,Stephanie Daignault-Newton,Jessica Waninger,Sara Journey,Zoey Chopra,Alangoya Tezel,Bruce G. Redman,Leslie A. Fecher,Michael D. Green,Ajjai Alva,Christopher D. Lao +10 more
TL;DR: In this article, the authors retrospectively analyzed a cohort of metastatic or unresectable melanoma patients who were treated with combination ipilimumab/nivolumab (ipi/nivo) or anti-PD-1 monotherapy.
Journal ArticleDOI
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
TL;DR: The lack of overall survival benefit in clinical trials of patients with high-risk stage II and stage III disease raises the question of whether it is more efficacious to treat when there is residual microscopic disease, or to wait until the disease recurs.
Journal ArticleDOI
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
F.S. Hodi,V. Chiarion-Sileni,Rene Gonzalez,J.-J. Grob,Piotr Rutkowski,Charles Lance Cowey,Christopher D. Lao,Dirk Schadendorf,John Wagstaff,R. Dummer,Pier Francesco Ferrucci,Michael Smylie,A. Hill,David Hogg,Ivan Marquez-Rodas,Joel Jiang,Jasmine I. Rizzo,James Larkin,Jedd D. Wolchok +18 more
Journal ArticleDOI
Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Georgina V. Long,Mohammed M. Milhem,Asim Amin,Christopher J. Hoimes,Theresa Medina,Robert M. Conry,Christopher D. Lao,Gregory A. Daniels,Sunil Reddy,Inderjit Mehmi,Robert H.I. Andtbacka,Minal A. Barve,M. Shaheen,T. Tueting,Michael Chisamore,B. Xing,Albert Candia,Erick Gamelin,Robert Janssen,Antoni Ribas +19 more